Details of the Drug

General Information of Drug (ID: DM3O8QY)

Drug Name
Degarelix
Synonyms
Degarelix; 214766-78-6; UNII-SX0XJI3A11; SX0XJI3A11; CHEMBL415606; Uglypeptide1; Degarelix (INN/USAN); Degarelix [USAN:INN:BAN]; SCHEMBL1397034; GTPL5585; HSDB 7817; CHEBI:135961; HY-16168A; BDBM50102450; AKOS030526717; AN-5181; RL02641; DB06699; CS-5350; FE200486 (AS ACETATE SALT); QC-10170; Z-3147; D08901; 766D786; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 1632.3
Topological Polar Surface Area (xlogp) 3.5
Rotatable Bond Count (rotbonds) 41
Hydrogen Bond Donor Count (hbonddonor) 17
Hydrogen Bond Acceptor Count (hbondacc) 18
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.68 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 41.5 - 70.2 days [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.1% [3]
Vd
The volume of distribution (Vd) of drug is 40.9 L [4]
Chemical Identifiers
Formula
C82H103ClN18O16
IUPAC Name
(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2,6-dioxo-1,3-diazinane-4-carboxamide
Canonical SMILES
C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C
InChI
InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
InChIKey
MEUCPCLKGZSHTA-XYAYPHGZSA-N
Cross-matching ID
PubChem CID
16136245
ChEBI ID
CHEBI:135961
CAS Number
214766-78-6
DrugBank ID
DB06699
TTD ID
D0Y7KH

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gonadotropin-releasing hormone receptor (GNRHR) TT8R70G GNRHR_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Degarelix (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Degarelix and Ivosidenib. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Degarelix and Gilteritinib. Acute myeloid leukaemia [2A60] [17]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Degarelix and Oliceridine. Acute pain [MG31] [17]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Degarelix and Ivabradine. Angina pectoris [BA40] [17]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Degarelix and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [18]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Degarelix and Levalbuterol. Asthma [CA23] [19]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Degarelix and Eribulin. Breast cancer [2C60-2C6Y] [17]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Degarelix and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [17]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Degarelix and Olodaterol. Chronic obstructive pulmonary disease [CA22] [20]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Degarelix and Vilanterol. Chronic obstructive pulmonary disease [CA22] [19]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Degarelix and Osilodrostat. Cushing syndrome [5A70] [17]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Degarelix and Deutetrabenazine. Dystonic disorder [8A02] [17]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Degarelix and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [17]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Degarelix and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [17]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Degarelix and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Degarelix and Crizotinib. Lung cancer [2C25] [21]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Degarelix and Ceritinib. Lung cancer [2C25] [22]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Degarelix and Osimertinib. Lung cancer [2C25] [23]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Degarelix and Selpercatinib. Lung cancer [2C25] [17]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Degarelix and Lumefantrine. Malaria [1F40-1F45] [24]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Degarelix and Vemurafenib. Melanoma [2C30] [22]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Degarelix and LGX818. Melanoma [2C30] [17]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Degarelix and Siponimod. Multiple sclerosis [8A40] [24]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Degarelix and Fingolimod. Multiple sclerosis [8A40] [22]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Degarelix and Ozanimod. Multiple sclerosis [8A40] [25]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Degarelix and Entrectinib. Non-small cell lung cancer [2C25] [17]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Degarelix and Rucaparib. Ovarian cancer [2C73] [17]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Degarelix and Triclabendazole. Parasitic worm infestation [1F90] [17]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Degarelix and Macimorelin. Pituitary gland disorder [5A60-5A61] [26]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Degarelix and Lefamulin. Pneumonia [CA40] [27]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Degarelix and LEE011. Solid tumour/cancer [2A00-2F9Z] [22]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Degarelix and Pitolisant. Somnolence [MG42] [17]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Degarelix and Lenvatinib. Thyroid cancer [2D10] [17]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Degarelix and Cabozantinib. Thyroid cancer [2D10] [17]
⏷ Show the Full List of 34 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5585).
2 ClinicalTrials.gov (NCT01512472) Firmagon (Degarelix) Intermittent Therapy. U.S. National Institutes of Health.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.
6 Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
11 Clinical pipeline report, company report or official report of Takeda (2009).
12 Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
13 Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
14 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
15 Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34.
16 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
21 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22 Canadian Pharmacists Association.
23 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
24 Cerner Multum, Inc. "Australian Product Information.".
25 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
26 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
27 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.